This multi-centre, randomized, double-blind, double-dummy, parallel-group study was designed to investigate the hypothesis of equivalent efficacy and comparable safety of two inhaled presentations of salmeterol/fluticasone propionate combination product (SALM/FP) 50/100 mg administered twice daily to patients with mild-to-moderate asthma for 12 weeks. The delivery systems were a 25/50 mg strength hydrofluoroalkane (HFA) metered-dose inhaler (MDI) and a Diskus TM inhaler (50/100 mg strength). A third group received FP 100 mg twice daily via a chlorofluorocarbon MDI (50 mg strength). A total of 497 patients aged 11-79 years with reversible airways obstruction who were symptomatic on inhaled corticosteroid (ICS) therapy and had room for improvement in lung function were randomized to treatment in a double-blind, parallel-group design (SALM/FP MDI: n¼165; SALM/ FP Diskus TM : n¼167; FP MDI: n¼165) for 12 weeks. A total of 383 patients completed the study according to the protocol.
Introduction
Although inhaled corticosteroids (ICS) are considered to be the first-line prophylactic treatment for patients with persistent asthma (1, 2) , individuals with more severe disease remain symptomatic despite taking these agents. For those patients who remain symptomatic on ICS therapy, therapeutic options include increasing the dose of ICS or adding a long-acting b 2 -agonist (1, 2) .
Many studies have now been published showing that the combination of a long-acting b 2 -agonist with an ICS provides greater improvement in lung function and symptom control than at least doubling the dose of ICS (3) (4) (5) (6) (7) (8) . Furthermore, it has been shown that this combination reduces the rate of exacerbations (9, 10) .
Based on the complementary roles of these two drug classes and the desire to simplify asthma therapy, the long-acting b 2 -agonist, salmeterol, and the ICS, fluticasone propionate (FP), have been combined in a single, multi-dose dry powder Diskus TM inhaler (Seretide  TM ) . A number of studies in both adults and children have established that salmeterol and FP have similar efficacy and tolerability whether they are administered via one Diskus TM inhaler (the combination product) or via two separate Diskus TM inhalers (11) (12) (13) (14) . More recently, a SALM/FP metered dose inhaler (MDI) has been developed to provide physicians and patients with an alternative choice of delivery system. Some patients prefer to use an MDI, particularly those who require a spacer. Selection of the most appropriate delivery device for each patient may facilitate compliance with inhaled asthma therapy and thereby contribute to greater asthma control.
The MDI is the most commonly prescribed inhalation device for the delivery of asthma therapy, with approximately 340 million units used world-wide every year (15, 16) . The popularity of the MDI is attributable to its proven effectiveness and ability to deliver a wide range of drugs (17) . Traditionally, MDIs have been formulated with a combination of the chlorofluorocarbon (CFC) propellants 11 and 12. However, because of the ozone-depleting potential of CFCs, the pharmaceutical industry has undertaken a major research programme to identify alternative propellants (18) . As part of this process, the hydrofluoroalkane (HFA) propellant, HFA 134a has been developed. HFA 134a does not deplete the ozone layer and is approved by European and other regulatory authorities worldwide for use as a propellant in MDIs. The SALM/FP MDI has therefore been formulated with HFA 134a rather than with CFC propellants.
Three strengths of the SALM/FP MDI have been developed each containing a constant dose of salmeterol 25 mg combined with FP 50, 125 or 250 mg per actuation. Each dose is given as two actuations. These three strengths correspond to the three strengths of the SALM/FP Diskus TM (50/100, 50/250 and 50/500 mg) and therefore provide the same flexibility of steroid dosing allowing a lower steroid dose to be used.
The aim of this study was to demonstrate equivalent efficacy and comparable safety of the lowest strength SALM/FP MDI (25/50 mg; two inhalations twice daily) and SALM/FP Diskus TM (50/100 mg; one inhalation twice daily) in adolescents and adults with reversible airways obstruction. A further objective was to show that the SALM/FP MDI was more efficacious and as safe as FP 100 mg twice daily administered via a CFC MDI, a wellestablished asthma therapy.
Methods

PATIENT POPULATION
Adolescent and adult patients aged 12 years or older were eligible for study entry if they had a documented clinical history of reversible airway obstruction, a smoking history of 510 pack-years and had been using ICS (beclomethasone dipropionate, budesonide or flunisolide 400-500 mg day 71 or FP 200-250 mg day
71
) for at least 4 weeks before entering the run-in period. Patients were subsequently randomized to study treatment if during the run-in period they had demonstrated room for improvement in lung function. This was defined as a mean morning peak expiratory flow (PEF) over the last 7 days of the run-in period of 450% and 585% of the PEF measured after inhalation of salbutamol (400 mg). In addition, they had to be symptomatic, i.e. have a cumulative total symptom score (daytime plus night-time) of 8 for the last 7 days of the run-in period, and be taking salbutamol 800 mg day
. Forced expiratory volume in 1 sec (FEV 1 ) at randomization had to be 450% of predicted normal.
Patients were excluded from the study if they had received a long-acting b 2 -agonist or oral b 2 -agonist within 2 weeks of the run-in period, changed their asthma medication or had a lower respiratory tract infection within 4 weeks of the run-in period or had an acute asthma exacerbation requiring hospitalization within 12 weeks of study entry. Other exclusion criteria included prior treatment with oral, depot or parenteral corticosteroids or combination therapy (containing a b 2 -agonist and/or ICS).
Written informed consent to participate in the study was obtained from each patient prior to entry. The study was approved by the local ethics committee for each centre and was conducted in accordance with the Declaration of Helsinki.
STUDY DESIGN
Sixty-nine centres in 10 countries participated in this randomized, double-blind, double-dummy, parallel-group study. The study comprised a 2-week run-in period, a 12-week treatment period and a 2-week follow-up period. During the run-in period, patients continued to take their usual ICS therapy, and salbutamol (Ventolin TM ) was provided for symptomatic relief. At the end of this period the patients discontinued their current ICS therapy and were randomized to one of the following three treatment groups: All other regular asthma therapy (including anti-cholinergics and theophylline) was continued provided that the dose remained constant. Patients were allowed to use a Volumatic TM spacer with the active or placebo MDI, provided it was used for the duration of the study.
ASSESSMENTS
Patients measured their daily morning and evening PEF, using a mini-Wright peak flow meter, before taking the study medication or rescue Ventolin TM . The highest of three measurements was recorded on a daily record card throughout the study, together with the daytime and nighttime use of as-needed salbutamol. Patients also kept a daily record card of their daytime symptom score using a sixpoint scale (0¼no symptoms during the day; 5¼symptoms so severe that the patient was unable to go to work or school or perform normal daily activities) and night-time symptom score using a 5-point scale (0¼no symptoms during the night; 4¼symptoms so severe that the patient could not sleep at all).
Clinic FEV 1 (highest of three measurements) was measured at the beginning and end of the run-in period and at weeks 2, 4, 8 and 12 of the treatment period. Patients were asked to withhold their rescue medication for at least 6 h before each clinic visit and to withhold their study medication on the morning of each visit. Whenever possible FEV 1 measurements were made at the same time of day at each clinic visit.
ADVERSE EVENTS
All adverse events occurring at any time during the study were recorded, irrespective of their likely causality. A serious adverse event was described as any event which was fatal, life-threatening, disabling or incapacitating, or which required or prolonged hospitalization.
Oropharyngeal examinations were performed before randomization and at weeks 4, 8 and 12 of the treatment period. If there was clinical evidence of Candida a swab was taken.
Blood samples were collected between 08.00 hours and 10.00 hours, at the end of the run-in and treatment periods, for routine biochemical and haematological analyses and measurement of morning serum cortisol concentrations. A physical examination was also performed and vital signs (blood pressure and heart rate) were monitored.
STATISTICAL ANALYSIS
The primary efficacy variable was mean morning PEF over weeks 1-12. This was analysed using both the intent-totreat (ITT) and per protocol populations (the ITT population with no major protocol violations). Based on a requirement for 90% power, a sample size of 165 patients per treatment group was required to demonstrate equivalence between the SALM/FP MDI and Diskus TM groups. The treatment groups were prospectively defined as equivalent if the 95% confidence intervals (CIs) for the treatment difference were between +15 l min 71 for both the ITT and per protocol populations (19) . Effects due to centre, sex, age, baseline lung function, spacer usage and previous ICS therapy were also tested for the primary efficacy variable.
The secondary efficacy measures included evening PEF, daytime and night-time symptom scores, use of as-required salbutamol and clinic FEV 1 . Both the ITT and per protocol populations were used to analyse mean evening PEF and clinic FEV 1 . All other secondary analyses were conducted using the ITT population. Differences between the SALM/ FP MDI and FP MDI groups were analysed; however, in order to reduce the effects of multiple testing there was no statistical comparison between the SALM/FP Diskus TM and FP MDI groups.
Change in PEF, PEF per cent predicted, circadian variation in PEF and clinic FEV 1 were analysed using analysis of covariance (ANCOVA), allowing for effects due to centre, sex, age and baseline. Symptom scores, percentage of symptom-free days and nights, and days and nights with no rescue salbutamol were analysed using the MannWhitney Wilcoxon sum test. Withdrawals were analysed using Fisher's exact test.
Serum cortisol data were logarithmically transformed and analysed using ANCOVA with covariates of age, sex, centre and log baseline. Least square means for the treatments were transformed back to the original scale and presented as geometric means.
Results
A total of 724 patients entered the run-in period, of whom 497 were subsequently randomized to treatment: 165 received the SALM/FP MDI, 167 the SALM/FP Diskus TM and 165 the FP MDI. After randomization, 67 patients were withdrawn, 20 (12%) in the SALM/FP MDI group, 22 (13%) in the SALM/FP Diskus TM group and 25 (15%) in the FP MDI group. Reasons for withdrawal included adverse events (seven, eight and 11 patients in the three groups, respectively), protocol violations (four, two and three patients, respectively), lost to follow-up (one, three and two patients, respectively), failure to fulfil the entry criteria (0, three, and three patients, respectively), lack of efficacy (one, two and 0 patients, respectively), noncompliance (two, one, and 0 patients, respectively) and other (five, three and six patients, respectively). The most common adverse event leading to withdrawal was a worsening of asthma symptoms.
The per protocol population comprised 383 patients (SALM/FP MDI: n¼128; SALM/FP Diskus TM : n¼131; FP MDI: n¼124). A total of 114 patients were excluded from the per protocol population; the most common reasons for exclusion were: PEF outside the stated range at baseline (450% and 585% of PEF measured after salbutamol use) (n¼52) and baseline symptom score 7 (n¼30).
With the exception of morning PEF at baseline, the three treatment groups were well matched for demographic and baseline characteristics (Table 1) . A similar number of patients used a spacer device throughout the study ( *Two male patients (one in the SALM/FP HFA MDI and one in the SALM/FP Diskus TM group) were aged 11 years. These two patients were included in the intent-to-treat but not in the per protocol population. Improvements in mean morning PEF were similar regardless of which ICS had been used prior to study entry. However, an interaction between treatment and spacer use was seen in the per protocol population (total of 59 patients used a spacer): the effect of treatment on mean morning PEF was apparently smaller in patients using the SALM/FP Diskus TM than in those on the SALM/FP MDI. As the former patients were using a spacer only for their placebo medication (via MDI), this is likely to be a chance occurrence.
Mean morning PEF, as a percentage of the maximum PEF recorded after salbutamol use, was 79% in all three groups at baseline and 89%, 88% and 84% in the SALM/ FP MDI, SALM/FP Diskus TM and FP MDI groups, respectively, during weeks 1-12, indicating that patients had not attained maximum PEF.
Mean evening PEF, and percent predicted mean morning and evening PEF improved from baseline in all three treatment groups, with the greatest improvement in the SALM/FP MDI and Diskus TM groups (Table 3) . The SALM/FP MDI produced significantly greater improvements in these secondary efficacy variables than the FP MDI during weeks 1-12 (Table 3) . Similarly, a decrease in circadian variation in PEF was reported in all three treatment groups, indicating improved asthma control (Table 3) .
CLINIC FEV 1
Clinic FEV 1 improved in all three groups during the treatment period (Table 4) . Increases from baseline of 17%, 15% and 15% were reported at week 12 in the SALM/FP MDI, SALM/FP Diskus TM and FP MDI groups, respectively. Differences between the SALM/FP MDI and the other two groups were not statistically significant.
SYMPTOM SCORES
The number of symptom-free days and nights increased in all three treatment groups ( Table 5 ). The median proportions of symptom-free days and nights over weeks [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] were similar in the SALM/FP MDI and Diskus TM groups (respectively: 55% and 52% for days and 71% and 78% for nights; Table 5 ). In comparison with the FP MDI group, the SALM/FP MDI group reported significantly more symptom-free days (weeks 1-12: 55 vs. 25%; 95% CI: 719, 72; P¼0?001) (Fig. 2) , and more symptom-free nights (71 vs. 53%; 95% CI: 714, 0; P¼0?063) ( Table 5 ).
USE OF RESCUE MEDICATION
There were similar increases in the number of salbutamolfree days and nights in the SALM/FP MDI and Diskus TM groups (Table 5 ). During weeks 1-12, the respective median proportions of salbutamol-free days in these groups were 73% and 75%, and 90% and 93% for nights. Significantly more salbutamol-free days and nights were reported in the SALM/FP MDI group than in the FP MDI group for all except one assessment period (salbutamol-free nights during weeks 5-8) (Table 5 ). 
ADVERSE EVENTS
The overall incidence of adverse events was similar in the three treatment groups. Eighty-two patients (50%) in the SALM/FP MDI group, 95 (57%) in the SALM/FP Diskus TM group and 90 (55%) in the FP MDI group experienced at least one adverse event during treatment. The most common adverse events (reported by 4% of patients in any one group) are summarized in exacerbations (n¼5), breast neoplasia (n¼1) and events associated with the gastrointestinal system (n¼2) and ear, nose and throat (n¼1). The only serious adverse events considered by the investigator to be drug-related were asthma exacerbations in two patients (one each in the SALM/FP MDI and Diskus TM groups).
SERUM CORTISOL
After 12 weeks of treatment there was a small increase in mean morning serum cortisol levels from baseline in all three groups (geometric mean ratios 1?08 to 1?21) ( 
Discussion
This study demonstrates that the SALM/FP MDI and the SALM/FP Diskus TM inhaler are clinically equivalent when administered at a dose of 50/100 mg twice daily to patients with mild to moderate asthma who were symptomatic on ICS alone. The SALM/FP MDI was equivalent to the SALM/FP Diskus TM in terms of the primary efficacy variable, improvement in morning PEF from baseline during weeks 1-12. The two treatments were also comparable with respect to the secondary efficacy measures, including daily symptom scores, evening PEF and use of rescue salbutamol. These results are consistent with those from a similar clinical study at higher doses of SALM/FP (50/500 mg twice daily), in which HFA 134a MDI and Diskus TM presentations had equivalent efficacy (20) . To ensure that true clinical equivalence of the two SALM/FP delivery systems could be established, strict patient entry criteria were set to avoid making comparisons at the plateau of the dose-response curve. This was achieved by randomizing only those patients who showed room for improvement in lung function during the run-in period (defined as a mean morning PEF of 450% and 585% of the PEF measured after inhalation of salbutamol) (21) . Indeed, patients still had scope for improvement at the end of the study; the mean morning PEF achieved during weeks 1-12 was 84-89% in the three groups (values expressed as a percentage of the maximum achievable PEF recorded in response to salbutamol). These findings suggest that some patients could have achieved better asthma control if they had been treated with a higher dose of SALM/FP; however, the patient selection criteria allowed differences to be detected between the SALM/FP MDI and FP MDI groups, so confirming that the study design was appropriate.
Two study populations were assessed for efficacy, the ITT and per protocol populations. The results for the two populations were similar, indicating that the exclusion of a large number of patients from the per protocol population did not alter the conclusions of the study. Furthermore, a sufficient number of patients was enrolled in the ITT population (n¼497) to ensure adequate power for the primary efficacy analysis. The patients in each treatment group were well matched for baseline and demographic characteristics, except for a difference in morning PEF at baseline in the SALM/FP MDI and Diskus TM groups; this was taken into account by presentation of the results as adjusted means.
The SALM/FP MDI was superior to the FP MDI for the primary efficacy variable, change in mean morning PEF from baseline, and for many of the secondary efficacy measures. The overall superior efficacy of SALM/FP confirms the findings of earlier studies comparing combination or concurrent therapy with these two drugs with FP alone (14, 22) . There was no significant difference between the SALM/FP and FP MDIs with respect to the percentage of symptom-free nights; however, this may have been because the overall incidence of night-time symptoms was too low to enable a difference to be detected at this level of power (median symptom score of 0 over weeks 1-12 in all groups).
The SALM/FP MDI and Diskus TM and the FP MDI were equally well tolerated. The incidence and pattern of adverse events were as expected for a clinical trial of this nature in a population of asthmatic patients. The incidence of oral candidiasis was low in all three treatment groups. There was no evidence of adrenal suppression in any treatment group. Effects on hypothalamic-pituitary adrenal (HPA) axis function were similar for the SALM/FP MDI and Diskus TM at equivalent FP doses, and HPA function tended to improve during the study compared with baseline in all three groups. Although morning serum cortisol is not the most sensitive measure of HPA axis function, it is a practical means of assessment in large multi-centre studies and can be used to detect clinically significant differences between treatments if they exist.
There has been concern that regular treatment with inhaled b 2 -agonists may mask any deterioration in inflammation and increase the rate and severity of asthma exacerbations (23) . However, there is a significant body of clinical evidence to suggest that such deterioration in asthma control does not occur. Exacerbation rates were reduced when a long-acting b 2 -agonist was added to ICS therapy for 12 months in the FACET study (9, 24) ; a recent meta-analysis of other studies reported similar findings (10) . The FACET study also demonstrated that treatment with a long-acting b 2 -agonist had no effect on the severity of exacerbations (24) . In addition, retrospective analysis has shown that a long-acting b 2 -agonist does not alter the physicians' or patients' recognition of signs and symptoms of deteriorating asthma (25) .
Although the duration of this study was relatively short (12 weeks), the incidence and severity of asthma exacerbations was low and similar in all three treatment groups, further supporting this finding.
The SALM/FP MDI is the first asthma therapy in which two complementary classes of drug, an ICS and a longacting b 2 -agonist, are combined in a single MDI formulated with a non-CFC propellant. The Diskus TM dry powder inhaler provides consistent dose delivery (26, 27) , has low resistance compared with other dry powder inhalers (28, 29) and is easy to use and well accepted by physicians and patients (30, 31) . Giving patients and physicians a means of delivering SALM/FP via a single inhaler, and offering a choice of two devices for such delivery, may each have a beneficial effect on patient compliance with asthma therapy.
In conclusion, the efficacy and safety of SALM/FP 50/ 100 mg twice daily is comparable whether administered via the HFA 134a MDI or Diskus TM , giving patients a choice of delivery systems while retaining the simplicity of prescribing. This should also help patients who are switched to SALM/FP therapy from other asthma treatments; those who remain uncontrolled on ICS or b 2 -agonists alone can continue to use the MDI rather than learning how to use a new device, and those who are taking a long-acting b 2 -agonist and an inhaled corticosteroid concurrently via separate MDIs will need only a single inhaler.
